India's Cabinet Committee on Economic Affairs, chaired by Prime Minister Narendra Modi, has decided to block China's Shanghai Fosun Pharmaceutical Group Co's proposed $1.3 billion takeover of Indian drugmaker Gland Pharma Ltd, Bloomberg reported, citing people familiar with the matter.
Both companies have not been formally notified of the move yet, the report said.
Finance Ministry spokesman D.S. Malik told Reuters that the report was "totally speculative" and that the matter had not yet come before the Cabinet Committee on Economic Affairs (CCEA).
Fosun, Gland Pharma and the CCEA did not immediately respond to requests for comment.
The deal was announced last July when Shanghai Fosun agreed to buy an 86 percent stake in KKR & Co-backed Gland Pharma.
The current stand-off on a plateau next to the mountainous Indian state of Sikkim, which borders China, has ratcheted up tension between the neighbours, who share a 3,500-km (2,175-mile) frontier, large parts of which are disputed.
Gland Pharma, based in Hyderabad, owns four factories from where it supplies a variety of injectables - widely used medicines administered through vials, syringes, bags and pumps, which are harder to make than regular medicines.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)